NCT03158064View on ClinicalTrials.gov

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Germ Cell TumorNonseminomatous Germ Cell TumorSeminomaGerminomatous Germ Cell TumorDysgerminomaPineal Germ Cell Tumor
Interventions
DRUG

Durvalumab

1500 mg by IV

DRUG

Tremelimumab

"75 mg by IV~\*300mg"

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03158064 - Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | Biotech Hunter | Biotech Hunter